Celltech Pharmaceuticals Inc.

XOMA, COMV, CWCO, ANPI, WEL, MESA Expected To Be Lower After Earnings Releases on Monday.
M2 Presswire; 11/5/2009; 3477 words; ...CWCO), Angiotech Pharmaceuticals (NASDAQ: ANPI...Before COMV Comverge, Inc. 12 quarters Q3 Before...MESA Mesa Air Group, Inc. 12 quarters Q4 During...expression of recombinant pharmaceutical products to biotechnology...agreements with Genentech, Inc.; UCB Celltech; National ...

Other News To Note.
BIOWORLD Today; 11/4/2009; 2767 words; ...Applied Genetics Inc. Dermatics. o...disclosed. o Cellomics Inc., of Pittsburgh...therapeutics. o Celltech Group plc, of...Fellner, who was Celltech's CEO since 1990...chairman. o CeNeS Pharmaceuticals plc, of Cambridge...three of its four pharmaceutical products from a...Columbia ...

Genentech, Xenova In Potential $63M Deal For OX40 Program.
BIOWORLD Today; 11/4/2009; 1229 words; ...existing relationship with Celltech Group plc, also of Slough, under which Celltech is developing an anti...the merger with Cantab Pharmaceuticals plc, of Cambridge...and Seattle Genetics Inc. formed a potential...deals.o In February, Celltech Group and Seattle Genetics...

Crohn's Drug Fails In Phase II; Millennium Awaits More Data.
BIOWORLD Today; 11/4/2009; 1375 words; ...II trial, Millennium Pharmaceuticals Inc. said the drug hit a...Francisco-based Genentech Inc., with which Millennium...Pa.-based Centocor Inc.'s anti-inflammatory...marketing agreement between Celltech Group plc, of Slough...

Celltech, BMS Stop Development Of NSCLC Product After Phase II.
BIOWORLD Today; 11/4/2009; 1126 words; ...products will target. Celltech also is working with Wyeth Pharmaceuticals, of Madison, N...other indications, Celltech and Cambridge, Mass.-based Biogen Inc. are developing a...Crohn's Disease. Celltech is working with Peapack...